Zealand Pharma CEO Adam Steensberg discusses the company’s new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule..
Back to Health Page
Zealand Pharma CEO Adam Steensberg discusses the company’s new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule.
Zealand Pharma CEO Adam Steensberg discusses the company’s new collaboration and licensing agreement with Roche as well as the commercial opportunities for its amylin analog molecule..
Back to Health Page